ইস্রায়েল - হিব্রু - Ministry of Health

bristol, myers squibb (israel) limited - entecavir 1 mg - film coated tablets - entecavir - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. this indication is based on clinical trial data in patients with hbeag positive and hbeag negative hbv infection, nucleoside naive patients and patients with lamivudine-refractory hepatitis b.decompensated liver disease.

ইস্রায়েল - হিব্রু - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 4.5 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m

ইস্রায়েল - হিব্রু - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 6 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m

ইস্রায়েল - হিব্রু - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 9 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m

ইস্রায়েল - হিব্রু - Ministry of Health

abbvie biopharmaceuticals ltd, israel - leuprorelin acetate - leuprorelin acetate 11.25 mg - leuprorelin

ইস্রায়েল - হিব্রু - Ministry of Health

abbvie biopharmaceuticals ltd, israel - leuprorelin acetate - leuprorelin acetate 11.25 mg - leuprorelin

ইস্রায়েল - হিব্রু - Ministry of Health

abbvie biopharmaceuticals ltd, israel - leuprorelin acetate - leuprorelin acetate 3.75 mg - leuprorelin

ইস্রায়েল - হিব্রু - Ministry of Health

abbvie biopharmaceuticals ltd, israel - leuprorelin acetate - leuprorelin acetate 3.75 mg - leuprorelin

ইস্রায়েল - হিব্রু - Ministry of Health

megapharm ltd - nitisinone - קפסולה קשיחה - nitisinone 2 mg - nitisinone - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

ইস্রায়েল - হিব্রু - Ministry of Health

megapharm ltd - nitisinone - קפסולה קשיחה - nitisinone 5 mg - nitisinone - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine